---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-025781"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-08-05T11:00:10+00:00"
generated_at: "2026-08-05T11:05:11.813635+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eton licenses late-stage ASN-001 (timolol gel) for infantile hemangiomas; $3M upfront

## Summary
- Upfront license fee $3M to Auson; milestones up to $33.5M based on sales thresholds; tiered royalties 10-15%.
- Phase II/III trial: 56% (BID) and 42% (TID) elimination/near-elimination at week 24 vs 15% placebo.
- NDA submission planned for 2H 2027; potential approval and launch in 2028.
- Estimated 20,000-30,000 patients annually; complementary to HEMANGEOL, leveraging existing commercial infrastructure.
- Patent protection through 2044; additional patent application pending.

## SEC filing metadata
- accession: 0001437749-26-025781
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-08-05T11:00:10+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/0001437749-26-025781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/eton20260803_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-025781
- JSON: https://secwatch.observer/filing/0001437749-26-025781.json
- Plain text: https://secwatch.observer/filing/0001437749-26-025781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.